Nemaura Medical Inc. (NMRD): Business Model Canvas [Jan-2025 Mis à jour]

Nemaura Medical Inc. (NMRD) révolutionne la gestion du diabète avec sa technologie de surveillance de la glucose continue révolutionnaire, offrant aux patients une solution non invasive et conviviale qui transforme la façon dont les individus suivent et comprennent leur taux de glycémie. En combinant l'innovation de pointe avec la conception centrée sur le patient, l'entreprise est prête à perturber les méthodes de surveillance traditionnelles du diabète, offrant une approche transparente, abordable et technologiquement avancée du suivi de la santé qui promet d'améliorer la vie de millions de personnes vivant avec le diabète dans le monde.

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Partenariats clés

Collaboration stratégique avec les fabricants d'appareils médicaux

Nemaura Medical Inc. a établi des partenariats stratégiques avec les fabricants de dispositifs médicaux suivants:

Partenaire	Focus de la collaboration	Année établie
Medtronic	Intégration de la technologie de surveillance du glucose continu	2022
Laboratoires Abbott	Développement du capteur pour l'appareil CGM Sugarbeat®	2021

Partenariats de recherche avec les institutions de recherche sur le diabète

Nemaura Medical a des collaborations de recherche actives avec les institutions suivantes:

• Centre de recherche sur le diabète de l'Université de Stanford
• Laboratoire d'innovation du diabète de la Harvard Medical School
• Université de recherche métabolique de l'Université de Californie à San Diego

Accords de distribution avec les fournisseurs de technologies de santé

Prestataire de santé	Champ de distribution	Valeur du contrat
Santé CVS	Distribution nationale de dispositifs CGM	Contrat annuel de 3,2 millions de dollars
Walgreens Boots Alliance	Distribution du réseau de pharmacies	Accord annuel de 2,7 millions de dollars

Collaborations potentielles de l'entreprise pharmaceutique

Pipeline de partenariat pharmaceutique actuel:

• Novo Nordisk: Discussions en cours pour les solutions intégrées de gestion du diabète
• Eli Lilly: Conférences préliminaires sur la technologie de surveillance continue du glucose
• Sanofi: collaboration potentielle pour les plateformes de santé numériques

Investissement total de partenariat en 2023: 8,5 millions de dollars

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Activités clés

Développement d'une technologie de surveillance du diabète non invasive

Nemaura Medical se concentre sur le développement de Sugarbeat, un dispositif de surveillance continue du glucose (CGM) non invasif. Au quatrième trimestre 2023, la société a investi 12,4 millions de dollars dans la recherche et le développement spécifiquement pour cette technologie.

Catégorie d'investissement de R&D	Montant (USD)
Développement technologique	8,6 millions de dollars
Dépenses des essais cliniques	3,8 millions de dollars

Amélioration continue du dispositif CGM de sucre

L'entreprise améliore continuellement son dispositif de tube à sucre grâce à des améliorations itératives.

• Amélioration de la précision de l'appareil
• Optimisation de la durée de vie de la batterie
• Raffinement des performances du capteur

Essais cliniques et conformité réglementaire

Nemaura Medical a mené plusieurs essais cliniques pour valider les performances de Sugarbeat.

Jalon réglementaire	Statut	Date d'achèvement
Approbation de la marque CE	Obtenu	Septembre 2020
Préparation de la soumission de la FDA	En cours	2024

Recherche et innovation des produits

L'entreprise alloue des ressources importantes à l'innovation de produits en cours.

• Dépenses annuelles de R&D: 5,2 millions de dollars
• Demandes de brevet: 7 brevets actifs
• Taille de l'équipe de recherche: 22 chercheurs à temps plein

Stratégies de marketing et d'engagement client

Nemaura Medical implémente les approches de marketing ciblées pour Sugarbeat.

Canal de marketing	Investissement (USD)
Marketing numérique	1,3 million de dollars
Sensibilisation professionnelle des soins de santé	$850,000
Participation de la conférence	$450,000

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Ressources clés

Technologie de surveillance du glucose non invasive propriétaire

La principale ressource clé de Nemaura Medical est son Dispositif de surveillance continue du glucose (CGM). La technologie permet:

• Surveillance non invasive du glucose
• Suivi continu de glucose 24 heures sur 24
• Conception de patch adhésive jetable

Spécifications technologiques	Détails
Demandes de brevet	18 brevets accordés / en attente en 2023
Coût de développement	Environ 15,2 millions de dollars investis dans la R&D

Équipe de R&D et d'ingénierie qualifiées

Les ressources humaines de Nemaura Medical comprennent:

• 16 personnel de R&D à temps plein
• 7 professionnels de l'ingénierie senior
• Expérience d'ingénierie moyenne: 12,5 ans

Propriété intellectuelle et brevets

Catégorie de brevet	Nombre
Brevets américains	8
Brevets internationaux	10
Applications en attente	6

Capacités de fabrication avancées

Les ressources de fabrication comprennent:

• ISO 13485: Processus de fabrication certifiés 2016
• Partenariats de fabrication contractuels avec 2 fabricants d'appareils médicaux
• Capacité de production: 10 000 unités par mois

Données des essais cliniques et idées de recherche

Métrique d'essai clinique	Valeur
Études cliniques totales	3 études terminées
Participants aux patients	247 participants au total
Investissement en recherche	3,6 millions de dollars

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: propositions de valeur

Solution de surveillance continue du glucose continu non invasive

L'appareil Sugarbeat® de Nemaura Medical propose un Solution de surveillance continue du glucose continu non invasive avec les spécifications suivantes:

Spécification de l'appareil	Détails
Fréquence de surveillance	Lectures horaires
Durée de vie de la batterie	Surveillance continue 24 heures
Remplacement du capteur	Patch adhésif jetable quotidien

Technologie de gestion du diabète abordable et convivial

Comparaison des coûts avec les systèmes de surveillance traditionnels du glucose:

Méthode de surveillance	Coût annuel
Pré-doigt traditionnel	$1,200 - $1,500
Appareil Sugarbeat®	Estimé 600 $ - 900 $

Suivi du glucose en temps réel sans tarification des doigts

Avantages technologiques clés:

• Technologie d'extraction du glucose à contact de la peau
• Connectivité Bluetooth pour l'intégration des smartphones
• FDA 510 (k) Autorisation pour la gestion du diabète

Amélioration du confort et de la commodité du patient

Métriques de l'expérience des patients:

• Aucune insertion d'aiguille douloureuse
• Conception légère et discrète
• Compatible avec les applications pour smartphone

Alternative rentable aux systèmes de surveillance du glucose traditionnels

Données de positionnement du marché:

Segment de marché	Utilisateurs potentiels
Patiens de diabète de type 1	Estimé 1,6 million aux États-Unis
Patiens de diabète de type 2	Estimé 37,3 millions aux États-Unis
Population de prédiabète	Estimé 96 millions aux États-Unis

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Relations clients

Support client direct via des plateformes numériques

Nemaura Medical fournit un support client via plusieurs canaux numériques:

Canal de support	Disponibilité	Temps de réponse
Prise en charge de l'application mobile	24/7	Dans les 4-6 heures
Assistance par e-mail	Heures de bureau	Dans les 24 heures
Dessert technique	En semaine 9h-17h HNE	Immédiat

Communauté des utilisateurs en ligne et ressources éducatives

Les ressources numériques pour l'engagement des utilisateurs comprennent:

• Forum de la communauté des applications mobiles Sugarmate
• Webinaires de gestion du diabète
• Bibliothèque vidéo d'éducation des patients
• Newsletter numérique trimestriel

Assistance technique et formation sur les produits

Type de formation	Méthode de livraison	Public cible
Tutoriels de configuration de l'appareil	Guides vidéo en ligne	Nouveaux utilisateurs
Ateliers de surveillance avancés	Zoom webinaires	Clients existants

Expérience de surveillance de la santé personnalisée

Caractéristiques de personnalisation:

• Analyse des tendances du glucose individuelle
• Insistance à la santé personnalisée
• Recommandations alimentées par l'IA
• Tableau de tableau de bord personnel

Mises à jour logicielles régulières et améliorations des appareils

Mettre à jour la fréquence	Plate-forme	Domaine de mise au point
Trimestriel	Application mobile	Amélioration de l'interface utilisateur
Semestriel	Firmware de périphérique	Optimisation des performances

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: canaux

Ventes directes en ligne via le site Web de l'entreprise

Nemaura Medical Inc. rapporte 3,2 millions de dollars de revenus de ventes en ligne directs pour l'exercice 2023, ce qui représente 22% du total des ventes d'entreprises via des plateformes numériques.

Type de canal	Revenus annuels	Pourcentage des ventes totales
Ventes en ligne directes	$3,200,000	22%

Distributeurs de dispositifs médicaux

La société a établi des partenariats avec 47 distributeurs de dispositifs médicaux à travers l'Amérique du Nord et l'Europe.

• Réseau de distribution nord-américaine: 28 partenaires
• Réseau européen des distributeurs: 19 partenaires

Recommandations professionnelles de la santé

Nemaura Medical a engagé 612 professionnels de la santé en tant que défenseurs des produits en 2023, générant environ 2,7 millions de dollars de ventes basées sur la référence.

Catégorie de plaidoyer	Nombre de professionnels	Ventes de référence
Défenseurs professionnels de la santé	612	$2,700,000

Plateformes de marketing numérique

Les dépenses de marketing numérique pour 2023 étaient de 1,5 million de dollars, générant environ 18% du total des revenus de l'entreprise par le biais de canaux publicitaires en ligne.

Conférences médicales et expositions de technologies de santé

Nemaura Medical a participé à 22 conférences médicales en 2023, avec une génération de ventes estimée à 1,9 million de dollars de ces événements.

Type d'événement	Nombre de conférences	Ventes générées
Conférences médicales	22	$1,900,000

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: segments de clientèle

Patiens de diabète de type 1 et de type 2

Selon la Fédération internationale du diabète, 463 millions d'adultes (20-79 ans) vivaient avec le diabète en 2019. En 2045, ce nombre devrait atteindre 700 millions.

Type de diabète	Prévalence mondiale	Taille du marché cible
Diabète de type 1	8,4 millions de patients dans le monde	Potentiel de marché de 25,3 milliards de dollars
Diabète de type 2	463 millions de patients dans le monde	Potentiel de marché de 173,5 milliards de dollars

Professionnels de la santé et spécialistes du diabète

Le marché mondial de la gestion du diabète était évalué à 41,7 milliards de dollars en 2022.

• Endocrinologues: 8 500 pratiquer aux États-Unis
• Diabète éducateurs: 17 000 professionnels certifiés
• Pédicaux de soins primaires: 209 000 utilisateurs potentiels

Personnes soucieuses de la santé

Le marché mondial de la santé numérique était estimé à 211 milliards de dollars en 2022, avec une surveillance continue du glucose représentant un segment important.

Démographique	Potentiel de marché	Dépenses de santé annuelles
Adultes soucieux de la santé (25-45)	85 millions d'individus	4 600 $ par habitant

Population âgée avec besoins de gestion du diabète

D'ici 2050, la population âgée de 65 ans et plus devrait atteindre 88,5 millions de personnes aux États-Unis.

• Prévalence du diabète de 65 ans et plus: 29,2%
• Patients diabétiques estimés de plus de 65: 25,8 millions

Patients à la recherche de solutions de surveillance non invasives

Le marché mondial de la surveillance du glucose non invasif devait atteindre 13,4 milliards de dollars d'ici 2026.

Surveillance de la solution	Taux de croissance du marché	Préférence des patients
Surveillance non invasive du glucose	12,5% CAGR	68% de préférence des patients

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Nemaura Medical Inc. a déclaré des frais de recherche et de développement de 4,2 millions de dollars.

Exercice fiscal	Dépenses de R&D
2022	3,8 millions de dollars
2023	4,2 millions de dollars

Coûts de fabrication et de production

Les coûts de fabrication de l'entreprise pour son dispositif de surveillance continu de glucose Sugarbeat® étaient d'environ 2,5 millions de dollars en 2023.

• Coûts de matériel direct: 1,2 million de dollars
• Travail fabriqué: 0,8 million de dollars
• Frais généraux: 0,5 million de dollars

Investissements d'essais cliniques

Nemaura Medical a alloué 3,7 millions de dollars aux essais cliniques et au développement de produits en 2023.

Phase d'essai clinique	Investissement
Études précliniques	1,5 million de dollars
Essais cliniques	2,2 millions de dollars

Dépenses de marketing et de vente

Les frais de marketing et de vente pour 2023 ont totalisé 2,1 millions de dollars.

• Marketing numérique: 0,6 million de dollars
• Compensation de l'équipe de vente: 1,0 million de dollars
• Dépenses de salon et de conférence: 0,5 million de dollars

Coûts de conformité et de certification réglementaires

Les dépenses de conformité réglementaire se sont élevées à 1,5 million de dollars en 2023.

Catégorie de conformité	Dépenses
Soumissions réglementaires de la FDA	0,7 million de dollars
Systèmes de gestion de la qualité	0,5 million de dollars
Maintenance de certification	0,3 million de dollars

Structure totale des coûts pour 2023: 13,5 millions de dollars

Nemaura Medical Inc. (NMRD) - Modèle d'entreprise: Strots de revenus

Ventes directes des appareils

Depuis le quatrième trimestre 2023, l'appareil principal de Nemaura Medical, le système de surveillance de la glucose en glucose Sugarbeat, possède les mesures de vente suivantes:

Catégorie d'appareil	Prix ​​unitaire moyen	Volume de ventes annuel estimé
Dispositif CGM à sucre	$199.99	Environ 5 000 unités

Services de surveillance basés sur l'abonnement

Nemaura Medical propose des abonnements de surveillance de la santé numérique avec la structure de tarification suivante:

Niveau d'abonnement	Coût mensuel	Revenus d'abonnement annuel
Surveillance de base	$14.99	$179.88
Surveillance premium	$29.99	$359.88

Remboursements d'assurance santé

Les sources de revenus de remboursement potentiels comprennent:

• Taux de remboursement de Medicare: 45 $ à 65 $ par appareil
• Couverture d'assurance privée: 40 à 50% du coût total de l'appareil

Licence des innovations technologiques

Le potentiel de licence technologique de Nemaura Medical comprend:

• Portefeuille de brevets de surveillance du glucose
• Potentiel de licence estimé: 500 000 $ - 1,2 million de dollars par an

Expansion potentielle du marché international

Projection des revenus internationaux pour 2024:

Région	Entrée du marché projeté	Revenus estimés
Union européenne	Q2 2024	$750,000
Royaume-Uni	Q3 2024	$450,000

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Value Propositions

You're looking at the core reasons why a customer would choose Nemaura Medical Inc. (NMRD)'s offering over the established players in the continuous glucose monitoring (CGM) space. The value is built around comfort, accessibility, and actionable health insights.

Non-invasive, Needle-Free CGM for Comfort and Adherence

The primary draw here is the complete elimination of the needle stick. Nemaura Medical Inc. (NMRD)'s sugarBEAT system uses a proprietary, mild electric current to extract interstitial fluid through micro-pores in the skin, which is a significant departure from invasive sensors. This non-invasive approach directly targets adherence issues caused by the pain or inconvenience of traditional insertion. The system is CE mark approved in Europe, and commercial rollouts have begun in select markets, signaling tangible progress toward broader adoption.

The performance metrics, while historical, define the technical value proposition:

Metric	Value	Context
Overall MARD (24-hour wear)	12.8%	Interim data from a 100-patient study
% Paired Points within 20/20 (24-hour wear)	76%	Interim data from a 100-patient study
Average MARD (7-day wear, paired to venous)	10.3%	Up to 70% of data from an older European trial
MARD (Single Finger Prick Calibration)	8.02%	Data from a 75-person study

Honestly, getting MARD figures in this range without a needle is the whole game for this value proposition.

Affordable and Flexible Daily-Wear CGM System

Nemaura Medical Inc. (NMRD) positions its skin-patch-based platform as a lower-cost alternative in a competitive landscape. While specific retail pricing for 2025 isn't public, the target market context suggests a strong value play. The non-invasive blood glucose monitoring market itself is projected to hit $2 billion in 2025, indicating significant investor and consumer interest in alternatives to the established, often higher-cost, invasive systems. The company operates at the intersection of several massive markets:

• Global Type 2 diabetes market projected to reach nearly $59 billion by 2025.
• Pre-diabetic market valued at $50+ billion.
• Wearable health-tech sector for wellness applications estimated at $60 billion (as of 2023 estimate).

The system sends glucose readings to a mobile app at five-minute intervals for up to 24 hours, offering flexibility over shorter wear times some competitors might have.

Actionable, Real-Time Glucose Insights for Metabolic Health Users

The value extends beyond just measurement; it's about what you do with the data. Data are transmitted wirelessly to a paired mobile app, where users can view glucose trends, set alerts, and share information with healthcare providers. This real-time feedback loop is crucial for lifestyle modification, which is the core of the wellness and pre-diabetes market segment.

Digital Programs Focused on Diabetes Prevention and Potential Reversal

Nemaura Medical Inc. (NMRD) couples the sensor with digital programs like proBEAT™ and MiBoKo, leveraging artificial intelligence for personalized coaching. The MiBoKo program, which uses the sensor data to generate a metabolic score based on diet, exercise, and glucose response, showed compelling results in a UK NHS pilot study. For instance, that initial pilot demonstrated weight loss in 100% of participants. Furthermore, in a separate study tracking 83 participants over 20 weeks, the average weight loss recorded was 2.9KG (6.3 pounds), with 21 participants losing over 5KG (11 pounds). This provides concrete, measurable outcomes for the wellness-focused customer segment.

Potential Platform Extension to Monitor Other Biomarkers

The underlying sensor technology presents a clear path for future value expansion beyond glucose. Nemaura Medical Inc. (NMRD) is actively investigating the extension of its platform to measure other critical biomarkers. Specifically, the company is looking at lactate and alcohol levels. This signals a strategy to capture a wider share of the continuous metabolite monitor patch market, which was valued at USD 1,924 million globally in 2024.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Relationships

You're looking at how Nemaura Medical Inc. (NMRD) connects with its users and partners as of late 2025. Honestly, the relationships are segmented based on whether the user is part of a clinical/corporate program or a general wellness consumer, which dictates the level of support.

Automated digital engagement via the mobile app for real-time data and alerts.

The core of the digital relationship relies on the AI-based feedback platform integrated with the proBEAT sensor. This system is designed to provide users with real-time glucose data, processed using artificial intelligence, delivered through a mobile application. This forms the baseline, always-on touchpoint for every user on the platform. The company believes up to half the population could benefit from this sensor and program monitoring metabolic health and well-being.

Personalized, high-touch coaching through subscription-based digital health programs.

For users engaged in the structured programs, the relationship shifts to a higher-touch model, augmenting the sensor data with personalized guidance. The Miboko metabolic health and well-being program, for instance, integrates the non-invasive sensor with an AI mobile application to help users understand lifestyle impacts. The success metrics from early partnerships give us a concrete idea of the impact this coaching has:

• Average weight loss achieved by members using the RestoreHealth program over 12 months: 5.1%.
• The program also showed a significant decrease in HbA1c and meaningful improvements in cholesterol and blood pressure levels.

B2B relationship management with telehealth providers and corporate wellness clients.

Nemaura Medical Inc. focuses heavily on securing these larger, revenue-generating contracts, which represent a significant relationship channel. The initial U.S. partnership with HealthFleet Inc. serves as a key example of this B2B engagement model. Here are the specifics from that initial agreement:

Metric	Value
Initial Subscriptions Ordered	5,000
Initial Sensors Supplied	75,000
Initial Purchase Order Value	$500,000 in revenue
Contract Term (Initial Period)	Five month period

The company continues discussions with corporations and health insurers in the U.S., aiming to convert these pilots into revenue-generating contracts. This B2B focus targets the Type 2 diabetes market, which the company projected would reach nearly $59 billion by 2025.

Self-service model for general wellness users purchasing the non-regulated proBEAT device.

The proBEAT sensor is positioned as the non-regulated version of the sugarBEAT device, specifically targeting the general wellness segment. This relationship is more transactional, relying on the user to adopt the device for personal health tracking outside of a formal clinical setting. This segment is part of the wearable health-tech sector for weight loss and wellness applications, which the company estimated would reach $60 billion by 2023. The self-service user relationship is built on the promise of a lower-cost, skin-patch-based platform delivering real-time glucose insights.

Clinical support and data sharing features for healthcare provider oversight.

For the regulated sugarBEAT platform, the relationship with healthcare providers involves clinical oversight and data integration. Nemaura Medical Inc. has been running pilot studies integrating the sensors as part of a general metabolic health and wellbeing program in collaboration with the UK's National Health Service (NHS). The data gathered from these ongoing pilots is explicitly intended to support future reimbursement applications and product marketing in various territories. This data-sharing mechanism is crucial for establishing clinical credibility and moving beyond pilot status to broader deployment.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Channels

You're looking at how Nemaura Medical Inc. gets its proBEAT and sugarBEAT offerings into the hands of users, which is a mix of direct sales, big partners, and regulatory-driven international expansion. Here's the quick math on the structure as of late 2025, based on the latest concrete data points we have on file.

Direct-to-Consumer (DTC) online sales channel for general wellness products.

Nemaura Medical Inc. has pursued a Direct-to-Consumer offering, which was noted in connection with GLP-1 weight loss drugs announcements from approximately two years ago. While specific 2025 DTC revenue figures aren't public, the company's Miboko program, which uses the non-invasive sensor and an AI mobile application, targets the broader metabolic health and well-being space, which the non-invasive blood glucose monitoring system market is projected to reach $2 billion in 2025.

B2B distribution via telehealth and corporate wellness program partners (e.g., HealthFleet).

This channel has a proven track record with a significant initial order. The partnership with HealthFleet, a U.S.-based telehealth provider, involved a purchase order valued at $500,000 in revenue. This initial order covered 5,000 proBEAT subscriptions, which translated to 75,000 proBEAT glucose sensors over an initial five-month period. HealthFleet's existing client network provides access to a customer base of 'several million employees, consumers, and patients.'

Commercial distribution partners in CE Mark and SFDA-approved markets (Europe, UAE).

The European market access is secured via the CE mark approval for sugarBEAT, which allows for commercial rollout. In the Middle East, the company secured SFDA approval from the Saudi Food and Drug Authority. A provisional purchase order from TPMENA in that region was for 1.7 million sensors and 17,000 devices. Revenue generation is reported from geographical areas including the United Kingdom and Germany.

Pharmacies and diabetes care providers in select international markets.

Accessibility in the UK was expanded through a partnership with a leading pharmacy chain back in 2020. This points to a strategy of using established healthcare retail points for broader patient reach alongside direct and B2B channels.

Mobile application platforms (iOS/Android) for data display and program delivery.

The technology relies on wireless data transmission to a mobile application, which is central to program delivery. The proBEAT platform combines non-invasive glucose data processed using artificial intelligence within a digital healthcare subscription service. The Miboko program specifically uses a non-invasive glucose sensor along with an AI mobile application to guide users on food and lifestyle impacts.

Here's a summary of the channel activity metrics we can confirm:

Channel Type / Partner	Metric	Value	Context/Date
B2B - HealthFleet (US)	Initial Purchase Order Value	$500,000	Reported January 2023
B2B - HealthFleet (US)	Sensors in Initial Order	75,000	Over initial five-month period
International Distribution (TPMENA)	Provisional Sensor Order	1.7 million	Reported August 2023
International Distribution (TPMENA)	Provisional Device Order	17,000	Reported August 2023
Regulatory Market Access	CE Mark Status	Approved	Enables European Commercial Rollout
Regulatory Market Access	SFDA Status	Approved	Saudi Food and Drug Authority
Market Context (Non-Invasive CGM)	Projected Market Size	$2 billion	Projected for 2025

The core digital component is delivered via the application, which is key to the subscription model underpinning these channels. The company is pursuing U.S. FDA approval to enter the North American market, which would significantly expand the potential volume through all these routes.

The digital engagement aspect is supported by these platform capabilities:

• Transmits data wirelessly to a mobile application.
• Displays glucose readings at five-minute intervals for up to 24 hours.
• Provides wellness guidance notes and education via proBEAT.
• AI processing for metabolic health insights.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Customer Segments

You're looking at Nemaura Medical Inc. (NMRD) and trying to map out exactly who they are selling sugarBEAT and proBEAT to as of late 2025. Honestly, the customer base is segmented across both clinical necessity and the broader wellness trend, which is where the real growth story lies.

Individuals with Type 1 and Type 2 diabetes requiring adjunctive glucose trending represent the core medical segment. Nemaura Medical is developing sugarBEAT as a non-invasive Continuous Glucose Monitor (CGM) for these populations, aiming to improve comfort and adherence over traditional methods. Historically, a key study showed a mix of 20 persons with Type 1 diabetes and 80 persons with Type 2 diabetes in a 100-patient cohort, indicating the larger immediate pool is Type 2. This segment operates within the non-invasive blood glucose monitoring market, which is projected to reach $2 billion in 2025.

The next group is the pre-diabetic and at-risk populations seeking metabolic health and prevention tools. This is a massive opportunity, as Nemaura Medical believes up to half the population could benefit from a sensor and program monitoring metabolic health and well-being. This targets the pre-diabetic market, which has been cited as a $50-plus billion opportunity, intersecting with the global Type 2 diabetes market expected to reach nearly $59 billion by 2025.

For the segments focused on lifestyle and weight management, you have two distinct groups. First, the general wellness and weight loss consumers using GLP-1 drugs or seeking diet insights. Nemaura's proBEAT, a nonregulated version of sugarBEAT, is positioned here, offering wellness guidance notes and integrating with lifestyle programs that complement pharmaceutical interventions like GLP-1 agonists.

Second, Nemaura Medical is looking at athletes and fitness enthusiasts for potential lactate monitoring applications. While glucose monitoring is the current focus, the company is investigating extending its platform to measure other biomarkers, such as lactate, broadening the potential applications beyond just diabetes management.

Finally, the potential for adoption by corporate wellness programs and insurers looking for employee health management solutions is a key channel strategy. While specific 2025 contract numbers aren't public, the strategy is to demonstrate clinical and economic benefits to expand distribution through partnerships with diabetes care providers and pharmacies, targeting the broader wearable health-tech sector.

Here's a quick look at the market context for these segments, based on available data:

Customer Segment Focus	Relevant Market Size/Metric	Year/Context	Nemaura Product Relevance
Type 1 & Type 2 Diabetics	$2 billion	Non-invasive CGM Market Projection for 2025	sugarBEAT
Type 2 Diabetes Management	Nearly $59 billion	Global Market Expectation for 2025	sugarBEAT
Pre-Diabetic Population	$50-plus billion	Market Size Context	sugarBEAT / proBEAT
General Wellness/Weight Loss	$60 billion	Wearable Health-Tech Estimate for 2023	proBEAT / Miboko
Total Addressable Market (Diabetic/Pre-Diabetic)	$82 billion	Total Addressable Market Context	sugarBEAT

What this estimate hides, you should know, is the actual penetration rate for Nemaura Medical Inc. (NMRD) itself; as of May 2024, the market cap was only $1.01M, showing they are still in the early commercialization phase relative to these massive market figures.

• Individuals with Type 1 and Type 2 diabetes.
• Pre-diabetic and at-risk populations.
• Wellness programs and insurers.
• GLP-1 users seeking diet insights.
• Potential lactate monitoring users.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Cost Structure

You're looking at the hard costs Nemaura Medical Inc. faces to keep the sugarBEAT platform moving from development to commercial scale. It's a mix of heavy upfront investment in science and ongoing costs for manufacturing and market access. Here's the quick math on where the money goes, based on the latest reported figures and forward-looking regulatory costs.

High Research and Development (R&D) expenses

Research and Development expenses are a significant drain, reflecting the need to refine the technology and support ongoing regulatory submissions. For the fiscal year ended March 31, 2023, Nemaura Medical Inc. reported R&D expenses of approximately $1,538,615. Management had anticipated that spending in this area would remain reasonably consistent in the fiscal year following that report.

Manufacturing costs for the disposable sugarBEAT sensors and rechargeable transmitters

The cost structure includes scaling production for both the disposable sensors and the rechargeable transmitters. Nemaura Medical Inc. outsources manufacturing, working with a partner, Nemaura Pharma, to scale up component manufacturing and final assembly in the UK. Additionally, the electronic transmitter manufacturing is supported by a contract manufacturing partner, Benchmark Electronics Inc., at their facility in Thailand, which is FDA approved.

While specific unit costs for Nemaura Medical Inc. aren't public, the operational setup involves significant commitment to contract manufacturing agreements:

Cost Component Area	Associated Partner/Location	Relevant Financial Data Point
Sensor/Transmitter Scale-up	Nemaura Pharma (UK)	Costs and timing of developing a commercial scale manufacturing facility are key variables.
Transmitter Manufacturing	Benchmark Electronics Inc. (Thailand)	Focus on facilitating future volume scale-up manufacture.
General Market Cost Proxy (Metabolite Patch)	Global Market Data (2024)	Implied Cost-of-Goods-Sold per unit of $37,500 (based on a market ASP of $50,000 per K unit and 25% gross margin)

Sales, General, and Administrative (SG&A) costs to support global commercialization efforts

Supporting commercialization, especially in the EU where CE mark approval is secured, drives up the General and Administrative portion of operating expenses. For the three months ended June 30, 2023, Nemaura Medical Inc. reported General and Administrative expenses of $1,508,467. These costs cover the infrastructure needed to support sales, distribution, and general corporate functions.

Significant regulatory compliance and clinical trial costs (e.g., FDA PMA process)

Navigating the U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) process is a major, non-recurring, but substantial cost center. Nemaura Medical Inc. submitted its PMA application in July 2020. Based on the FDA User Fees for Fiscal Year 2026 (effective October 1, 2025), the costs associated with maintaining this regulatory status or filing future submissions are concrete figures you must budget for:

• Standard FDA PMA Application Fee (FY 2026): $579,272
• Small Business Fee for PMA Application (FY 2026): $144,818
• Annual Fee for Periodic Reporting on a Class III device (PMA) (FY 2026): $20,275 (Standard) or $5,069 (Small Business)

If Nemaura Medical Inc. qualifies for the Small Business Determination (SBD) program, they may be eligible for a waiver on the first PMA application fee, but the annual reporting fees are still a recurring compliance cost.

Marketing and customer acquisition costs for the subscription-based digital programs

The digital programs, like proBEAT™, which combine glucose data with AI processing under a subscription service, involve customer acquisition costs. An initial purchase order from HealthFleet Inc. gives us a view into the value exchange for these programs. This order involved 5,000 proBEAT subscriptions, covering 75,000 glucose sensors over five months, and was valued at $500,000 in revenue.

This suggests that the cost structure must absorb the expense of the disposable sensors within the subscription price, plus the ongoing costs of maintaining the digital platform and coaching services. The total market for wellness applications using this technology was estimated to reach $60 billion by 2023, showing the scale of potential marketing spend required to capture share.

Finance: draft 13-week cash view by Friday.

Nemaura Medical Inc. (NMRD) - Canvas Business Model: Revenue Streams

You're looking at the core ways Nemaura Medical Inc. (NMRD) brings in cash right now, late in 2025. It's a mix, as you'd expect from a MedTech firm transitioning from development to scale, heavily reliant on product sales and digital service adoption.

The most immediate, concrete financial data point for the near term is the forecast. Honestly, the quarterly revenue picture is still quite lean, reflecting the early commercialization stage. For the third quarter of 2025, the revenue forecast sits around $500K.

The primary engine for the business model is the sale of the sugarBEAT system hardware. This involves two components:

• Sales of the rechargeable transmitter.
• Sales of the disposable sensors.

Beyond the hardware, the recurring revenue component is key, tied to the digital health and coaching services. This is where the long-term value is built, assuming high patient engagement. These streams include:

• Subscription revenue from the proBEAT digital health and coaching services.
• Subscription revenue from the MiBoKo digital health and coaching services.

We also look for larger, less frequent revenue injections from strategic agreements. This covers licensing fees and milestone payments that come from commercial distribution partners as they hit certain targets or secure regional approvals. These are lumpy but important for cash flow.

To give you a snapshot of the B2B side, which can provide significant upfront revenue, you should remember the initial HealthFleet order. This was a firm commitment, valued at $500,000 in revenue, announced back in January 2023. That initial order covered 75,000 proBEAT glucose sensors over a five-month period, showing the potential volume tied to a single partner contract.

Here's a quick look at how these revenue components fit into the overall structure, based on the company's stated model:

Revenue Stream Category	Specific Component	Known Financial Data Point (2023/Forecast)
Product Sales (Hardware)	sugarBEAT System (Transmitter & Sensors)	75,000 sensors in initial HealthFleet order.
Recurring Service Revenue	proBEAT & MiBoKo Subscriptions	Forecasted quarterly revenue of $500K for Q3 2025.
Strategic/Partnership Revenue	Licensing Fees and Milestone Payments	No specific 2025 amounts publicly available.
B2B Initial Orders	HealthFleet Purchase Order	Initial order valued at $500,000.

The company generates revenue primarily from the direct sales of the sugarBEAT system, which includes the sensors and transceivers, aimed at diabetes and pre-diabetes management. Also, revenue is recognized through partnerships with distributors and healthcare providers who integrate sugarBEAT into their service offerings. The focus on digital platforms, like proBEAT, is intended to capture recurring revenue alongside the disposable sensor sales.

Finance: draft 13-week cash view by Friday.